Search

Search Constraints

You searched for: Author/Creator Paris, Ida

Search Results

1. A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study. Issue 2 (1st February 2019)

2. Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti‐HER2 agents in the real world setting. Issue 7 (7th August 2019)

3. Erratum to 'Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis' [Eur J Cancer 149 (2021) 134–152]. (August 2021)

6. Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real‐world evidence. Issue 11 (15th January 2020)

7. Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer. (December 2022)

8. Needleoscopic-assisted risk-reducing bilateral salpingo-oophorectomy in BRCA1/2 mutation carriers: Peri-operative outcomes and psychological impact. (June 2022)

9. Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitors. (12th April 2020)

10. Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitors. (12th April 2020)